Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397954 · ClinicalTrials.gov registry record · Phase 2
A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
A Phase 2 study, sponsored by Ophthotech Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02397954: Completed Phase 2 study, sponsored by Ophthotech Corporation.
NCT02397954 is a Phase 2 study that has completed, run by Ophthotech Corporation. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02397954, a Phase 2 study, has completed, sponsored by Ophthotech Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).
Primary Outcome
Number of participants with \>15 ETDRS letter loss (with calculated percentage)
Interventions
- DRUG Avacincaptad Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-03-12 |
| Est. Completion | 2015-10-23 |
| Phase | Phase 2 |
What the finished NCT02397954 record still lists
NCT02397954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Avacincaptad Pegol is the first listed.
NCT02397954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02397954 about?
NCT02397954 is a clinical study titled "A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)". The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).
What is the current status of trial NCT02397954?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-03-12. Estimated completion is 2015-10-23.
What interventions are being tested in trial NCT02397954?
The interventions under investigation include: Avacincaptad Pegol (DRUG).
Who is sponsoring clinical trial NCT02397954?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02397954's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI